Full-year 2021 sales at Chemours (Wilmington, Delaware, USA; www.chemours.com) soared 28% to USD 6.3 bn (EUR 5.6 bn), thanks to its biggest business segment, Titanium Technologies (TiT). Adjusted EBITDA rose nearly by half to USD 1.31 bn and is forecast this year to be USD 1.3 bn-USD 1.425 bn, or flat at a minimum and at most up 8.5% on expectations of the global economy continuing its recovery.

TiT saw full-year revenues jumping 40% to USD 3.4 bn, as demand recovered from pandemic-induced lows. Despite global logistics issues and feedstock disruptions, TiT improved on volume and pricing, which were both positive across all regions while currency changes offered some tailwinds. Adjusted EBITDA rose 59% to USD 809 mn with margins jumping 300 basis points to 24%.

Advanced Performance Materials segment sales increased 27% to USD 1.4 bn on strong performance across all end markets and geographies. Full-year adjusted EBITDA more than tripled to USD 261 mn.